| Literature DB >> 24456928 |
Catrin Tudur Smith1, Helen Hickey, Mike Clarke, Jane Blazeby, Paula Williamson.
Abstract
BACKGROUND: Research into the methods used in the design, conduct, analysis, and reporting of clinical trials is essential to ensure that effective methods are available and that clinical decisions made using results from trials are based on the best available evidence, which is reliable and robust.Entities:
Mesh:
Year: 2014 PMID: 24456928 PMCID: PMC3904160 DOI: 10.1186/1745-6215-15-32
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Figure 1Part of the on-line data collection form used in round three.
Definition of consensus
| Consensus in | Consensus that topic should be included as a priority for trials methodology research | 70% or more participants scoring as 7 to 9 AND < 15% participants scoring as 1 to 3 |
| Consensus out | Consensus that topic should not be included as a priority for trials methodology research | 70% or more participants scoring as 1 to 3 AND < 15% of participants scoring as 7 to 9 |
| No consensus | Uncertainty about importance of topic as a priority for trials methodology research | Anything else |
Figure 2Response pattern and characteristics of 48 Clinical Trials Unit (CTU) Directors at each round of Delphi process.
List of topics identified as priorities by more than one Clinical Trials Unit (CTU) Director from round one (primary list) ordered by round three priority ranks
| | | | ||||||
|---|---|---|---|---|---|---|---|---|
| | | |||||||
| Methods to boost recruitment | 0.0 | 43.8 | 56.3 | 0.0 | 16.7 | 83.3 | Consensus in | 1 |
| Choosing appropriate outcomes to measure | 3.1 | 28.1 | 68.8 | 0.0 | 29.2 | 70.8 | Consensus in | 2 |
| Methods to minimise attrition | 6.3 | 40.6 | 53.1 | 0.0 | 29.2 | 70.8 | Consensus in | 2 |
| Methods to minimise bias in trials when blinding is not possible | 0.0 | 40.6 | 59.4 | 0.0 | 33.3 | 66.7 | | 4 |
| Pragmatic trials | 0.0 | 56.3 | 43.8 | 0.0 | 45.8 | 54.2 | | 5 |
| Design and analysis of pilot/feasibility trials | 6.3 | 46.9 | 46.9 | 4.2 | 41.7 | 54.2 | | 6 |
| Calculating sample size | 21.9 | 31.3 | 46.9 | 12.5 | 33.3 | 54.2 | | 7 |
| Methods for dealing with missing data | 3.1 | 59.4 | 37.5 | 0.0 | 58.3 | 41.7 | | 8 |
| Phase II trials | 15.6 | 50.0 | 34.4 | 16.7 | 50.0 | 33.3 | | 9 |
| Complex interventions | 3.1 | 62.5 | 34.4 | 0.0 | 70.8 | 29.2 | | 10 |
| Consent in emergency settings | 12.5 | 46.9 | 40.6 | 0.0 | 70.8 | 29.2 | | 10 |
| Methods for trial monitoring | 9.4 | 65.6 | 25.0 | 8.3 | 62.5 | 29.2 | | 12 |
| Adjustment for non-adherence to treatment protocol | 6.3 | 53.1 | 40.6 | 4.2 | 70.8 | 25.0 | | 13 |
| Stratified medicine design | 6.3 | 56.3 | 37.5 | 8.3 | 66.7 | 25.0 | | 14 |
| Primary care trials | 18.8 | 56.3 | 25.0 | 12.5 | 62.5 | 25.0 | | 15 |
| Interim analysis/Data Monitoring issues | 9.4 | 65.6 | 25.0 | 0.0 | 79.2 | 20.8 | | 16 |
| Adaptive designs | 0.0 | 62.5 | 37.5 | 4.2 | 75.0 | 20.8 | | 17 |
| Equivalence/non-inferiority trials | 12.5 | 62.5 | 25.0 | 12.5 | 66.7 | 20.8 | | 18 |
| Dealing with clustering effects | 6.3 | 65.6 | 28.1 | 4.2 | 79.2 | 16.7 | | 19 |
| Methods for economic analysis | 12.5 | 65.6 | 21.9 | 8.3 | 75.0 | 16.7 | | 20 |
| Cluster trials | 12.5 | 62.5 | 25.0 | 12.5 | 70.8 | 16.7 | | 21 |
| Evaluation of electronic data capture methods | 28.1 | 50.0 | 21.9 | 20.8 | 62.5 | 16.7 | | 22 |
| e-trials | 12.5 | 62.5 | 25.0 | 8.3 | 79.2 | 12.5 | | 23 |
| Multi-arm Multi-stage (MAMS) designs | 12.5 | 75.0 | 12.5 | 12.5 | 75.0 | 12.5 | | 24 |
| Stepped wedge designs | 15.6 | 65.6 | 18.8 | 16.7 | 75.0 | 8.3 | | 25 |
| Randomisation methods | 34.4 | 53.1 | 12.5 | 33.3 | 58.3 | 8.3 | | 26 |
| Multiplicity | 15.6 | 81.3 | 3.1 | 8.3 | 87.5 | 4.2 | | 27 |
| Radiotherapy study designs | 59.4 | 34.4 | 6.3 | 75.0 | 20.8 | 4.2 | Consensus out | 28 |
*Scores 1 to 3: topic not important; Scores 4 to 6: topic important but not critical; Scores 7 to 9: topic critical.
List of topics identified as priorities by one director from round one (secondary list) ordered by round three priority ranks
| | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgical trials | 30 | 10.0 | 43.3 | 46.7 | | 23 | 8.7 | 30.4 | 60.9 | | 1 |
| Use of routine data | 29 | 17.2 | 41.4 | 41.4 | | 23 | 8.7 | 39.1 | 52.2 | | 2 |
| Using previous evidence to inform design | 31 | 25.8 | 41.9 | 32.3 | | 23 | 13.0 | 43.5 | 43.5 | | 3 |
| Strategies of trial management | 30 | 23.3 | 43.3 | 33.3 | | 23 | 17.4 | 47.8 | 34.8 | | 4 |
| Assessing potential for and effect of attrition bias | 30 | 10.0 | 63.3 | 26.7 | | 23 | 4.3 | 65.2 | 30.4 | | 5 |
| Non-drug trials | 30 | 23.3 | 46.7 | 30.0 | | 22 | 13.6 | 59.1 | 27.3 | | 6 |
| QALYs for children | 31 | 29.0 | 41.9 | 29.0 | | 23 | 21.7 | 52.2 | 26.1 | | 7 |
| Calculating the target difference | 31 | 22.6 | 58.1 | 19.4 | | 23 | 13.0 | 65.2 | 21.7 | | 8 |
| Patient and public involvement | 30 | 26.7 | 60.0 | 13.3 | | 23 | 26.1 | 52.2 | 21.7 | | 9 |
| Strategies for adverse event reporting | 30 | 30.0 | 50.0 | 20.0 | | 23 | 21.7 | 60.9 | 17.4 | | 10 |
| Designs in rare diseases | 31 | 12.9 | 64.5 | 22.6 | | 23 | 13.0 | 73.9 | 13.0 | | 11 |
| Studies of diagnosis | 29 | 31.0 | 48.3 | 20.7 | | 23 | 39.1 | 47.8 | 13.0 | | 12 |
| Methods to adjust for baseline imbalance | 31 | 32.3 | 51.6 | 16.1 | | 23 | 47.8 | 39.1 | 13.0 | | 13 |
| Data modelling | 30 | 26.7 | 56.7 | 16.7 | | 22 | 31.8 | 59.1 | 9.1 | | 14 |
| Phase IV studies | 30 | 40.0 | 43.3 | 16.7 | | 22 | 54.5 | 36.4 | 9.1 | | 15 |
| Prevention studies | 30 | 20.0 | 60.0 | 20.0 | | 23 | 17.4 | 73.9 | 8.7 | | 16 |
| Trial reporting issues | 28 | 39.3 | 50.0 | 10.7 | | 23 | 26.1 | 65.2 | 8.7 | | 17 |
| Dose–response studies | 30 | 30.0 | 50.0 | 20.0 | | 23 | 34.8 | 56.5 | 8.7 | | 18 |
| Methods to measure pain | 31 | 41.9 | 48.4 | 9.7 | | 23 | 47.8 | 43.5 | 8.7 | | 19 |
| Low carbon trials | 30 | 70.0 | 23.3 | 6.7 | out | 23 | 78.3 | 13.0 | 8.7 | out | 20 |
| Eligibility criteria | 31 | 58.1 | 35.5 | 6.5 | | 22 | 63.6 | 31.8 | 4.5 | | 21 |
| Patient preference designs/issues | 29 | 20.7 | 69.0 | 10.3 | | 23 | 21.7 | 73.9 | 4.3 | | 22 |
| Design of paediatric investigation plans | 30 | 46.7 | 43.3 | 10.0 | | 23 | 56.5 | 39.1 | 4.3 | | 23 |
| Conflict of interest | 31 | 51.6 | 48.4 | 0.0 | | 23 | 65.2 | 30.4 | 4.3 | | 24 |
| Database trials | 30 | 33.3 | 63.3 | 3.3 | | 23 | 26.1 | 73.9 | 0.0 | | 25 |
| Crossover trials | 31 | 32.3 | 64.5 | 3.2 | | 23 | 39.1 | 60.9 | 0.0 | | 26 |
| Incorporating multiple disease/multiple treatment types into single protocols | 30 | 36.7 | 50.0 | 13.3 | 22 | 59.1 | 40.9 | 0.0 | 27 | ||
*Scores 1 to 3: topic not important; Scores 4 to 6: topic important but not critical; Scores 7 to 9: topic critical.